Timothy A. Springer - 14 Nov 2024 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Signature
/s/ Matthew Bartholomae, Attorney-in-Fact for Timothy A. Springer
Issuer symbol
RNAC
Transactions as of
14 Nov 2024
Net transactions value
+$7,373,527
Form type
4
Filing time
18 Nov 2024, 19:35:50 UTC
Previous filing
24 Oct 2024
Next filing
23 Dec 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNAC Common Stock Purchase $1,200,720 +74,157 +0.92% $16.19 8,097,923 14 Nov 2024 Direct F1
transaction RNAC Common Stock Purchase $377,436 +22,242 +0.27% $16.97 8,120,165 14 Nov 2024 Direct F2
transaction RNAC Common Stock Purchase $4,739,188 +277,246 +3.4% $17.09 8,397,411 15 Nov 2024 Direct F3
transaction RNAC Common Stock Purchase $684,447 +38,114 +0.45% $17.96 8,435,525 18 Nov 2024 Direct F4
transaction RNAC Common Stock Purchase $371,736 +20,181 +0.24% $18.42 8,455,706 18 Nov 2024 Direct F5
holding RNAC Common Stock 330,695 14 Nov 2024 By wife
holding RNAC Common Stock 529,798 14 Nov 2024 See Footnote F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $15.65 to $16.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $16.71 to $17.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $16.61 to $17.25. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $17.32 to $18.315. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F5 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.32 to $18.50. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F6 Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.